




Searching News Database: ProCellEx
HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
HSMN NewsFeed - 27 Dec 2017
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
HSMN NewsFeed - 17 Dec 2009
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
HSMN NewsFeed - 1 Dec 2009
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
HSMN NewsFeed - 27 Aug 2007
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD